Therapeutic options in patients with biochemical recurrence after radical prostatectomy

被引：8

作者：

Bratu, Ovidiu Gabriel ^{[1
,2
,3
]}

Diaconu, Camelia Cristina ^{[1
,4
]}

Mischianu, Dan Liviu Dorel ^{[1
,2
,3
]}

Constantin, Traian ^{[1
,5
]}

Stanescu, Ana Maria Alexandra ^{[1
]}

Bungau, Simona Gabriela ^{[6
]}

Ionita-Radu, Florentina ^{[7
]}

Marcu, Radu Dragos ^{[1
,2
]}

机构：

[1] Univ Med & Pharm Carol Davila, 8 Eroii Sanit St, Bucharest 050474, Romania

[2] Emergency Univ Cent Mil Hosp, Dept Urol, Bucharest 010825, Romania

[3] Acad Romanian Scientists, Bucharest 030167, Romania

[4] Clin Emergency Hosp Bucharest, Dept Internal Med, Bucharest 014461, Romania

[5] Prof Th Burghele Clin Hosp, Dept Urol, Bucharest 050659, Romania

[6] Univ Oradea, Fac Med & Pharm, Dept Pharm, Oradea 410073, Romania

[7] Emergency Univ Cent Mil Hosp, Dept Gastroenterol, Bucharest 010825, Romania

来源：

EXPERIMENTAL AND THERAPEUTIC MEDICINE | 2019年 / 18卷 / 06期

关键词：

prostate cancer; radical prostatectomy; biochemical recurrence; prostatic specific antigen; therapeutic options; SALVAGE RADIATION-THERAPY; FOLLOW-UP; CANCER; RADIOTHERAPY; CARCINOGENESIS; TOXICITY;

D O I：

10.3892/etm.2019.7916

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Prostate cancer is the second most common form of cancer in men in Europe. The primary treatment of this type of cancer is radical prostatectomy, which has shown good oncological results. Radical prostatectomy (open, laparoscopic or robotic) has high success and low morbidity rates in patients with localized prostate cancer. The life expectancy is >10 years after radical prostatectomy. Studies have shown that 20%-30% of the patients who have undergone radical prostatectomy can develop biochemical recurrence, which is monitored by using the value of the prostate-specific antigen (PSA). In some cases (patients with high-risk prostate cancer), adjuvant therapy after radical prostatectomy, such as radiotherapy or androgen deprivation therapy, can significantly reduce the risk of biochemical recurrence. The optimal management of recurrent disease remains uncertain. Recent literature was systematically reviewed regarding the management of biochemical recurrence and to compare clinical experience in literature studies.

引用

页码：5021 / 5025

页数：5

共 41 条

[1] Which Patients With Undetectable PSA Levels 5 Years After Radical Prostatectomy Are Still at Risk of Recurrence?-Implications for a Risk-adapted Follow-up Strategy [J].

Ahove, Deborah A. ;

Hoffman, Karen E. ;

Hu, Jim C. ;

Choueiri, Toni K. ;

D'Amico, Anthony V. ;

Nguyen, Paul L. .

UROLOGY, 2010, 76 (05) :1201-1205

[2]

[Anonymous], HUMAN SKIN CANCERS P

[3] Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer [J].

Beauval, Jean-Baptiste ;

Roumiguie, Mathieu ;

Filleron, Thomas ;

Benoit, Thibaut ;

de la Taille, Alexandre ;

Malavaud, Bernard ;

Salomon, Laurent ;

Soulie, Michel ;

Ploussard, Guillaume .

BMC UROLOGY, 2016, 16

[4] Prevalence of incidental prostate cancer: A systematic review of autopsy studies [J].

Bell, Katy J. L. ;

Del Mar, Chris ;

Wright, Gordon ;

Dickinson, James ;

Glasziou, Paul .

INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (07) :1749-1757

[5] A Systematic Review of the Role of Imaging before Salvage Radiotherapy for Post-prostatectomy Biochemical Recurrence [J].

Beresford, M. J. ;

Gillatt, D. ;

Benson, R. J. ;

Ajithkumar, T. .

CLINICAL ONCOLOGY, 2010, 22 (01) :46-55

[6] Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review) [J].

Boda, Daniel ;

Docea, Anca Oana ;

Calina, Daniela ;

Ilie, Mihaela Adriana ;

Caruntu, Constantin ;

Zurac, Sabina ;

Neagu, Monica ;

Constantin, Carolina ;

Branisteanu, Daciana Elena ;

Voiculescu, Vlad ;

Mamoulakis, Charalampos ;

Tzanakakis, George ;

Spandidos, Demetrios A. ;

Drakoulis, Nikolaos ;

Tsatsakis, Aristides M. .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 52 (03) :637-655

[7]

Boda D, 2013, CURR PROTEOMICS, V10, P237

[8] Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence [J].

Boorjian, Stephen A. ;

Thompson, R. Houston ;

Tollefson, Matthew K. ;

Rangel, Laureano J. ;

Bergstralh, Eric J. ;

Blute, Michael L. ;

Karnes, R. Jeffrey .

EUROPEAN UROLOGY, 2011, 59 (06) :893-899

[9] Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial [J].

Carrie, Christian ;

Hasbini, Ali ;

de Laroche, Guy ;

Richaud, Pierre ;

Guerif, Stephane ;

Latorzeff, Igor ;

Supiot, Stephane ;

Bosset, Mathieu ;

Lagrange, Jean-Leon ;

Beckendorf, Veronique ;

Lesaunier, Francois ;

Dubray, Bernard ;

Wagner, Jean-Philippe ;

Tan Dat N'Guyen ;

Suchaud, Jean-Philippe ;

Crehange, Gilles ;

Barbier, Nicolas ;

Habibian, Muriel ;

Ferlay, Celine ;

Fourneret, Philippe ;

Ruffion, Alain ;

Dussart, Sophie .

LANCET ONCOLOGY, 2016, 17 (06) :747-756

[10] The Role of Prostate-Specific Antigen in Prostate Cancer Screening [J].

Constantin, Traian Vasile ;

Madan, Victor Lucian ;

Constantin, Maria-Magdalena ;

Morariu, Silviu-Horia ;

Braticevici, Bogdan .

REVISTA ROMANA DE MEDICINA DE LABORATOR, 2014, 22 (02) :275-281

← 1 2 3 4 5 →